Skip to main content

Myovant Sciences Ltd.

MYOVDelisted Mar 10, 2023
Industry
Pharmaceutical Preparations
SEC CIK
0001679082

Myovant Sciences Ltd. was delisted on Mar 10, 2023; its insiders filed their last Form 4 on Mar 10, 2023; 118 institutions reported holding it in 13F filings for Q4 2022, worth $1.12B in total; no superinvestor held it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Oct 8, 2026, 1:55 PM ET

Revenue flow, FY2022

Where the revenue went in FY2022, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.

Net loss for FY2022: $206.0M (89.2% of revenue).

Income statement

Each column is one fiscal year, newest first.

Income statement of Myovant Sciences Ltd., annual
Line itemFY2022FY2021FY2020FY2019FY2018
Period endMar 31, 2022Mar 31, 2021Mar 31, 2020Mar 31, 2019Mar 31, 2018
Filing10-K10-K10-K10-K10-K
ReportedMay 10, 2022May 11, 2021May 18, 2020May 24, 2019Jun 7, 2018
Revenue$231.0M$59.3M–––
Operating expenses––$274.9M$264.8M$141.1M
Research and development$107.4M$136.7M$192.6M$222.6M$116.8M
Selling, general and administrative$259.4M$181.4M$82.3M$42.2M$24.2M
Operating income-$187.3M-$260.8M–-$273.1M-$143.0M
Interest expense$14.0M$10.4M–$8.82M$2.05M
Income tax$5.05M$336.0K$761.0K$476.0K$213.0K
Net income-$206.0M-$255.1M-$289.0M-$273.6M-$143.3M
EPS, basic$-2.22––––
EPS, diluted$-2.22––––
Weighted shares, basic93.0M––––
Weighted shares, diluted93.0M––––
Margins and growth
Operating margin-81.1%-439.6%–––
Net margin-89.2%-430.1%–––
Revenue growth, year over year+289.4%––––

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of Myovant Sciences Ltd., annual
Line itemFY2022FY2021FY2020FY2019FY2018
Period endMar 31, 2022Mar 31, 2021Mar 31, 2020Mar 31, 2019Mar 31, 2018
Filing10-K10-K10-K10-K10-K
ReportedMay 10, 2022May 11, 2021May 18, 2020May 24, 2019Jun 7, 2018
Cash and equivalents$406.7M$674.5M$76.6M$156.1M$108.6M
Short-term investments$27.5M$10.4M$3.00M––
Accounts receivable$23.3M$3.57M–––
Inventory$7.58M$2.61M–––
Total current assets$488.1M$704.6M$87.9M$166.8M$114.8M
Property, plant and equipment$2.94M$3.30M$2.50M$2.07M$1.27M
Total assets$520.0M$725.0M$105.9M$173.0M$119.1M
Accounts payable$12.3M$17.8M$15.3M–$4.58M
Short-term debt––$0$6.14M–
Total current liabilities$250.3M$281.3M$85.9M$72.0M$37.1M
Long-term debt––$0$93.2M$43.6M
Total liabilities$993.5M$1.08B$214.2M$168.6M$81.4M
Shareholders' equity-$473.5M-$354.0M-$108.3M$4.33M$37.7M

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of Myovant Sciences Ltd., annual
Line itemFY2022FY2021FY2020FY2019FY2018
Period endMar 31, 2022Mar 31, 2021Mar 31, 2020Mar 31, 2019Mar 31, 2018
Filing10-K10-K10-K10-K10-K
ReportedMay 10, 2022May 11, 2021May 18, 2020May 24, 2019Jun 7, 2018
Operating cash flow-$268.6M$370.6M-$221.2M-$224.1M-$117.3M
Capital expenditures$974.0K$1.77M$1.10M$1.24M$604.0K
Free cash flow-$269.5M$368.9M-$222.3M-$225.3M-$117.9M
Depreciation and amortization––$1.76M––
Stock-based compensation$38.9M$53.7M$40.3M$18.7M$11.6M
Investing cash flow-$18.0M-$9.21M-$3.94M-$1.24M-$604.0K
Financing cash flow$25.9M$238.0M$145.9M$273.9M$45.6M
Net change in cash-$260.7M$599.5M-$79.2M$48.6M-$72.2M
Ratio
Stock-based compensation, % of revenue16.9%90.5%–––

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for Myovant Sciences Ltd. by cover date
Cover dateShares outstandingChange in a yearFiling
Jan 20, 202397.2M+3.5%SEC
Oct 21, 202296.8M+3.7%SEC
Jul 25, 202295.9M+4.2%SEC
May 6, 202295.3M+4.2%SEC
Jan 21, 202293.9M+3.4%SEC
Oct 22, 202193.3M+3.0%SEC
Jul 23, 202192.1M+2.1%SEC
May 6, 202191.5M+1.8%SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.